Angel Pacheco Rivera, MD
General Practice · Hato Rey, PRNPI 1467446591
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,974 of the $7,165 with a category attached, or 83.4%. 22 manufacturers reported payments, led by AstraZeneca at 33.3% of the total. Reporting peaked in 2020 at $1,679 and has fallen 55.3% since, to $750 in 2025. Among general practice clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 254 payments — averaging $28.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Biocryst US Sales Co., LLC$638
- PBG Puerto Rico LLC$562
- GSK$376
- Boehringer Ingelheim$367
- plus $2K from 16 others
What the payments were for
- Consulting fees$1,10015%
- Food & beverage$5,97483%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 100 | $2,388 |
| E.r. Squibb & Sons, L.L.C. | 7 | $1,240 |
| Biocryst US Sales Co., LLC | 26 | $638 |
| PBG Puerto Rico LLC | 26 | $562 |
| GSK | 15 | $376 |
| Boehringer Ingelheim | 15 | $367 |
| Merck | 14 | $246 |
| Teva Pharmaceuticals USA, Inc. | 6 | $203 |
| Sanofi-aventis U.S. LLC | 9 | $188 |
| Amgen | 4 | $171 |
| Johnson & Johnson | 6 | $147 |
| Mylan Specialty L.p. | 6 | $134 |
| Lilly USA, LLC | 1 | $119 |
| Novo Nordisk | 6 | $118 |
| Eli Lilly Export S.A. Puerto Rico Branch | 4 | $64 |
| Exact Sciences | 2 | $57 |
| AbbVie | 2 | $49 |
| Viatris Specialty LLC | 1 | $28 |
| Pfizer | 1 | $24 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Gilead | 1 | $18 |
| Mylan LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,165 in reported general payments places this provider in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 324 | $486,376 |
| FarxigaDapagliflozin Propanediol | 202 | $276,439 |
| JanuviaSitagliptin Phosphate | 87 | $144,861 |
| TrulicityDulaglutide | 120 | $127,219 |
| TradjentaLinagliptin | 40 | $60,852 |
| XareltoRivaroxaban | 49 | $54,618 |
| GlyxambiEmpagliflozin/Linagliptin | 27 | $41,479 |
| SynthroidLevothyroxine Sodium | 335 | $40,773 |
| EliquisApixaban | 44 | $39,963 |
| DovatoDolutegravir Sodium/Lamivudine | 11 | $32,309 |
| LivaloPitavastatin Calcium | 39 | $28,439 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $26,977 |
| OzempicSemaglutide | 23 | $24,086 |
| Omega-3 Acid Ethyl Esters | 121 | $22,311 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $21,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Spiriva Respimat | $367 | $597,127407 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $2,388 | $305,214301 claims |
| MerckJanuvia, Janumet, Lagevrio (Eua) | $246 | $183,233117 claims |
| Lilly USA, LLCTrulicity | $119 | $127,219120 claims |
| Johnson & JohnsonXarelto | $147 | $54,61849 claims |
| AbbVieSynthroid, Lumigan | $49 | $45,604354 claims |
| PfizerEliquis | $24 | $39,96344 claims |
| Novo NordiskOzempic, Rybelsus | $118 | $38,37834 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $376 | $27,88446 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $188 | $26,59598 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,586 general practice providers in Puerto Rico.
Other general practice in Hato Rey
- Wilfredo CuevasSan Lorenzo$530K
- Julio BacoMayaguez$268K
- Soria Diaz BaezPonce$192K
- Carlos RomanCanovanas$140K
- William E TorresSan Juan$86K
- Rafael Mendoza RodriguezPonce$77K
- Frank Perez NogueiraSan German$70K
- Vivian Tamayo AgraitSan Juan$64K
- William Soto AvilesToa Baja$63K
- Jessica RosarioSanturce$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.